FIELD: biotechnology.
SUBSTANCE: invention relates to a polypeptide for cell labeling, and can be used in medicine.
EFFECT: obtained polypeptide containing extracellular domain of HER2 polypeptide can be used for selection of homogeneous products in genetic therapy.
22 cl, 9 dwg, 9 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
TRANSGENIC GENETIC LABELS AND METHODS OF USE | 2015 |
|
RU2822461C1 |
DRUG-REGULATED TRANSGENIC EXPRESSION | 2015 |
|
RU2751920C2 |
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2752275C2 |
MODIFIED HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS AND NON-T EFFECTOR CELLS, AND USE THEREOF | 2014 |
|
RU2733652C2 |
BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
Authors
Dates
2020-08-04—Published
2015-04-08—Filed